Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OptimizeRx CorpOPRX · Entity 213 | Chief Executive Officer | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OptimizeRx Corp
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,751 |
Reported balance
After 2026-08-20 transaction · row 1
1 source rowRow 1 · 2026-08-20 · Grant · Acquired 79,200 · Balance 262,751 F1: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on August 20, 2027, which is the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on August 20, 2027, which is the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2026 Filed Aug 24, 2026 19:14 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 1,737 | $7.71 | $13,392.27 |
DisclosureSEC source: 0001628280-26-058588 · wk-form4_1787598852.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,551 F1 · shares: These shares were withheld by the Issuer upon the vesting of restricted stock units to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 20:58 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 79,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-058673 · wk-form4_1787605097.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,751 F1 · shares: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on August 20, 2027, which is the first anniversary of the grant date. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:43 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 5,219 | $5.21 | $27,190.99 |
DisclosureSEC source: 0001628280-26-035998 · wk-form4_1779137014.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,288 F1 · shares: These shares were withheld by the Issuer upon the vesting of restricted stock units to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 23, 2025 Filed Dec 23, 2025 22:43 UTC Amendment | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 3,361 | $12.74 | $42,819.14 |
DisclosureSEC source: 0001628280-25-058799 · wk-form4a_1766529803.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,507 Read SEC document |
| December 23, 2025 Filed Dec 23, 2025 21:54 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 3,361 | $12.74 | $42,819.14 |
DisclosureSEC source: 0001628280-25-058768 · wk-form4_1766526886.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,507 F1 · security: These shares sold pursuant to a plan of disposition adopted on March 11, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · shares: These shares were withheld by the Issuer upon the vesting of restricted stock units to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 15:10 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 6,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-058412 · wk-form4_1766416206.xml · derivative · entry 3 Silvestro Stephen L · CIK 0001773461 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,547 Underlying: Common Stock · 6,546 shares Expires 2026-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning December 19, 2024, the first anniversary of the grant date. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 15:10 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 1,594 | $13.51 | $21,534.94 |
DisclosureSEC source: 0001628280-25-058412 · wk-form4_1766416206.xml · nonDerivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,868 F2 · balance_after: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 15:10 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 6,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-058412 · wk-form4_1766416206.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 22:26 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 6,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-044543 · wk-form4_1759875977.xml · derivative · entry 3 Silvestro Stephen L · CIK 0001773461 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,649 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning October 3, 2023, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning October 3, 2023, the first anniversary of the grant date. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 22:26 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 1,620 | $18.75 | $30,375.00 |
DisclosureSEC source: 0001628280-25-044543 · wk-form4_1759875977.xml · nonDerivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,916 F2 · shares: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 22:26 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 6,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-044543 · wk-form4_1759875977.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 21, 2025 Filed Aug 25, 2025 20:32 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantStock Option · Derivative | 35,156 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0001628280-25-041119 · wk-form4_1756153962.xml · derivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,156 Underlying: Common Stock · 35,156 shares Expires 2030-08-21 F2 · derivative.exercise_date: The stock option vests in three equal annual installments beginning August 21, 2026, the first anniversary of the grant date. Read SEC document |
| August 21, 2025 Filed Aug 25, 2025 20:32 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-041119 · wk-form4_1756153962.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,887 F1 · balance_after: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on August 21, 2026, which is the first anniversary of the grant date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:03 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantStock Option · Derivative | 80,884 | $0.00 Strike: $10.65 | $0.00 |
DisclosureSEC source: 0001628280-25-026499 · wk-form4_1747685005.xml · derivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,884 Underlying: Common Stock · 80,884 shares Expires 2029-05-15 F2 · derivative.exercise_date: The stock option vests in three equal annual installments beginning May 15, 2026, the first anniversary of the grant date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:03 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 46,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-026499 · wk-form4_1747685005.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,262 F1 · price: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on May 15, 2026, which is the first anniversary of the date of grant. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 14:18 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 1,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-009631 · wk-form4_1741097894.xml · derivative · entry 3 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F3 · derivative.exercise_date: The restricted stock units vested in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units vested in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 14:18 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 572 | $5.18 | $2,962.96 |
DisclosureSEC source: 0001628280-25-009631 · wk-form4_1741097894.xml · nonDerivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,314 F2 · shares: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 14:18 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 1,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-009631 · wk-form4_1741097894.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 18:39 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 2,298 | $6.64 | $15,258.72 |
DisclosureSEC source: 0001628280-25-006689 · wk-form4_1740076754.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,958 F1 · balance_after: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 23, 2024 Filed Dec 27, 2024 20:18 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantStock Option · Derivative | 77,742 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0001628280-24-052490 · wk-form4_1735330727.xml · derivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,742 Underlying: Common Stock · 77,742 shares Expires 2027-12-23 F2 · derivative.exercise_date: The stock option vests in three equal annual installments beginning December 23, 2025, the first anniversary of the grant date. Read SEC document |
| December 23, 2024 Filed Dec 27, 2024 20:18 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 41,408 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052490 · wk-form4_1735330727.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,256 F1 · shares: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on December 23, 2025, which is the first anniversary of the date of grant. Read SEC document |
| December 19, 2024 Filed Dec 21, 2024 00:47 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 6,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052286 · wk-form4_1734742056.xml · derivative · entry 3 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,093 Underlying: Common Stock · 6,546 shares Expires 2026-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning December 19, 2024, the first anniversary of the grant date. Read SEC document |
| December 19, 2024 Filed Dec 21, 2024 00:47 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 2,576 | $4.75 | $12,236.00 |
DisclosureSEC source: 0001628280-24-052286 · wk-form4_1734742056.xml · nonDerivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,848 F2 · balance_after: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 19, 2024 Filed Dec 21, 2024 00:47 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 6,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-052286 · wk-form4_1734742056.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 03, 2024 Filed Oct 8, 2024 01:24 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 6,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-042475 · wk-form4_1728350678.xml · derivative · entry 3 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,649 Underlying: Common Stock · 6,649 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning October 3, 2023, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning October 3, 2023, the first anniversary of the grant date. Read SEC document |
| October 03, 2024 Filed Oct 8, 2024 01:24 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 2,617 | $7.83 | $20,491.11 |
DisclosureSEC source: 0001628280-24-042475 · wk-form4_1728350678.xml · nonDerivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,878 F2 · price: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 03, 2024 Filed Oct 8, 2024 01:24 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 6,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-042475 · wk-form4_1728350678.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 02, 2024 Filed May 7, 2024 01:35 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-020821 · wk-form4_1715045740.xml · derivative · entry 3 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2024-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F3 · derivative.exercise_date: The restricted stock units cliff vested in full on May 2, 2024, the fifth anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units cliff vested in full on May 2, 2024, the fifth anniversary of the grant date. Read SEC document |
| May 02, 2024 Filed May 7, 2024 01:35 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 35,415 | $10.70 | $378,940.50 |
DisclosureSEC source: 0001628280-24-020821 · wk-form4_1715045740.xml · nonDerivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,846 F2 · shares: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 02, 2024 Filed May 7, 2024 01:35 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-020821 · wk-form4_1715045740.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. Read SEC document |
| March 15, 2024 Filed Apr 24, 2024 14:04 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 7,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-017545 · wk-form4_1713967450.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,706 F1 · shares: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on February 15, 2025, which is the first anniversary of the date of grant. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 21:20 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 1,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-009407 · wk-form4_1709760003.xml · derivative · entry 3 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,928 Underlying: Common Stock · 1,927 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 21:20 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 668 | $15.95 | $10,654.60 |
DisclosureSEC source: 0001628280-24-009407 · wk-form4_1709760003.xml · nonDerivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,956 F2 · shares: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 21:20 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 1,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-009407 · wk-form4_1709760003.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. Read SEC document |
| March 01, 2024 Filed May 7, 2024 01:34 UTC Amendment | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 572 | $15.95 | $9,123.40 |
DisclosureSEC source: 0001628280-24-020819 · wk-form4a_1715045619.xml · nonDerivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,261 F3 · shares: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. The original Form 4 filed by the Reporting Person reporting this transaction overstated the number of shares withheld by the Issuer. Read SEC document |
| March 01, 2024 Filed May 7, 2024 01:34 UTC Amendment | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 1,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-020819 · wk-form4a_1715045619.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · balance_after: A prior Form 4 filed by the Reporting Person failed to carry-forward previously owned shares, resulting in an understatement of the shares beneficially owned by the Reporting Person. The total amount beneficially owned has been adjusted to correct such inadvertent understatement. Read SEC document |
| February 15, 2024 Filed May 7, 2024 01:32 UTC Amendment | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 7,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-020817 · wk-form4a_1715045531.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,906 F1 · date: This Form 4 as originally filed reported in Table 1 a grant of Common Stock on March 15, 2024. However, this transaction occurred on February 15, 2024. F2 · shares: Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on February 15, 2025, which is the first anniversary of the date of grant. F3 · balance_after: A prior Form 4 filed by the Reporting Person failed to carry-forward previously owned shares, resulting in an understatement of the shares beneficially owned by the Reporting Person. The total amount beneficially owned has been adjusted to correct such inadvertent understatement. Read SEC document |
| December 19, 2023 Filed Feb 21, 2024 23:22 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 19,639 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-006018 · wk-form4_1708557741.xml · derivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,639 Underlying: Common Stock · 19,639 shares Expires 2026-12-19 F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning December 19, 2024, the first anniversary of the grant date. Read SEC document |
| December 19, 2023 Filed Feb 21, 2024 23:22 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantStock Option · Derivative | 19,639 | $0.00 Strike: $12.73 | $0.00 |
DisclosureSEC source: 0001628280-24-006018 · wk-form4_1708557741.xml · derivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,639 Underlying: Common Stock · 19,639 shares Expires 2026-12-19 F1 · derivative.exercise_date: The stock option vests in three equal annual installments beginning December 19, 2024, the first anniversary of the grant date. Read SEC document |
| October 03, 2023 Filed Oct 6, 2023 18:47 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 6,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-034060 · wk-form4_1696618044.xml · derivative · entry 3 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,298 Underlying: Common Stock · 6,649 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning October 3, 2023, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning October 3, 2023, the first anniversary of the grant date. Read SEC document |
| October 03, 2023 Filed Oct 6, 2023 18:47 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 1,952 | $7.06 | $13,781.12 |
DisclosureSEC source: 0001628280-23-034060 · wk-form4_1696618044.xml · nonDerivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,697 F2 · price: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 03, 2023 Filed Oct 6, 2023 18:47 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 6,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-034060 · wk-form4_1696618044.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:40 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionRestricted Stock Units · Derivative | 1,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-006261 · wf-form4_167787601944224.xml · derivative · entry 3 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,855 Underlying: Common Stock · 1,927 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:40 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 668 | $18.11 | $12,097.48 |
DisclosureSEC source: 0001628280-23-006261 · wf-form4_167787601944224.xml · nonDerivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,459 F2 · shares: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:40 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 1,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-006261 · wf-form4_167787601944224.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 17:18 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantStock Option · Derivative | 39,055 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0001628280-22-026033 · wf-form4_166499030249017.xml · derivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,055 Underlying: Common Stock · 39,055 shares Expires 2027-10-02 F3 · derivative.exercise_date: The stock option vests in three equal annual installments beginning October 3, 2023, the first anniversary of the grant date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 17:18 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 19,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-026033 · wf-form4_166499030249017.xml · derivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,947 Underlying: Common Stock · 19,947 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning October 3, 2023, the first anniversary of the grant date. F2 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning October 3, 2023, the first anniversary of the grant date. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 20:46 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 3,200 | $15.66 | $50,112.00 |
DisclosureSEC source: 0001213900-22-049032 · ownership.xml · nonDerivative · entry 1 Silvestro Stephen L · CIK 0001773461 · CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:46 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Units · Derivative | 5,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-010599 · ownership.xml · derivative · entry 2 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,782 Underlying: Common Stock · 5,782 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:46 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantStock Option · Derivative | 11,726 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001213900-22-010599 · ownership.xml · derivative · entry 1 Silvestro Stephen L · CIK 0001773461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,726 Underlying: Common Stock · 11,726 shares Expires 2027-03-01 F1 · derivative.exercise_date: The stock option vests in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.